» Articles » PMID: 21303939

GPR30 Activation Opposes Estrogen-dependent Uterine Growth Via Inhibition of Stromal ERK1/2 and Estrogen Receptor Alpha (ERα) Phosphorylation Signals

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2011 Feb 10
PMID 21303939
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Although estradiol-17β (E2)-regulated early and late phase uterine responses have been well defined, the molecular mechanisms linking the phases remain poorly understood. We have previously shown that E2-regulated early signals mediate cross talk with estrogen receptor (ER)-α to elicit uterine late growth responses. G protein-coupled receptor (GPR30) has been implicated in early nongenomic signaling mediated by E2, although its role in E2-dependent uterine biology is unclear. Using selective activation of GPR30 by G-1, we show here a new function of GPR30 in regulating early signaling events, including the inhibition of ERK1/2 and ERα (Ser118) phosphorylation signals and perturbation of growth regulation under the direction of E2 in the mouse uterus. We observed that GPR30 primarily localizes in the uterine epithelial cells, and its activation alters gene expression and mediates inhibition of ERK1/2 and ERα (Ser118) phosphorylation signals in the stromal compartment, suggesting a paracrine signaling is involved. Importantly, viral-driven manipulation of GPR30 or pharmacological inhibition of ERK1/2 activation effectively alters E2-dependent uterine growth responses. Overall, GPR30 is a negative regulator of ERα-dependent uterine growth in response to E2. Our work has uncovered a novel GPR30-regulated inhibitory event, which may be physiologically relevant in both normal and pathological situations to negatively balance ERα-dependent uterine growth regulatory functions induced by E2.

Citing Articles

Sex and estradiol effects in the rodent dorsal striatum.

Lewitus V, Kim J, Blackwell K Eur J Neurosci. 2024; 60(12):6962-6986.

PMID: 39573926 PMC: 11647445. DOI: 10.1111/ejn.16607.


Cardioprotective effects of GPER agonist in ovariectomized diabetic rats: reversing ER stress and structural changes.

Sirizi M, Esmailidehaj M, Mohamadi-Zarch S, Yadeghari M, Azizian H Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39298018 DOI: 10.1007/s00210-024-03438-4.


Low-molecular-weight estrogenic phytoprotein suppresses osteoporosis development through positive modulation of skeletal estrogen receptors.

Kubi J, Brah A, Cheung K, Chen A, Lee Y, Lee K Bioact Mater. 2024; 42:299-315.

PMID: 39290337 PMC: 11405634. DOI: 10.1016/j.bioactmat.2024.08.045.


G protein-coupled estrogen receptor 1 and collagen XVII endodomain expression in human cutaneous melanomas: can they serve as prognostic factors?.

Cakir U, Balogh P, Ferenczik A, Brodszky V, Krenacs T, Karpati S Pathol Oncol Res. 2024; 30:1611809.

PMID: 39252786 PMC: 11381273. DOI: 10.3389/pore.2024.1611809.


Current progress and prospects for G protein-coupled estrogen receptor in triple-negative breast cancer.

Zhang D, Chen H, Wang J, Ji J, Imam M, Zhang Z Front Cell Dev Biol. 2024; 12:1338448.

PMID: 38476263 PMC: 10928007. DOI: 10.3389/fcell.2024.1338448.


References
1.
Tsai M, OMalley B . Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994; 63:451-86. DOI: 10.1146/annurev.bi.63.070194.002315. View

2.
Filardo E, Quinn J, Bland K, Frackelton Jr A . Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000; 14(10):1649-60. DOI: 10.1210/mend.14.10.0532. View

3.
Weil B, Manukyan M, Herrmann J, Wang Y, Abarbanell A, Poynter J . Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery. 2010; 148(2):436-43. DOI: 10.1016/j.surg.2010.03.011. View

4.
Das S, Tan J, Johnson D, Dey S . Differential spatiotemporal regulation of lactoferrin and progesterone receptor genes in the mouse uterus by primary estrogen, catechol estrogen, and xenoestrogen. Endocrinology. 1998; 139(6):2905-15. PMC: 4277118. DOI: 10.1210/endo.139.6.6051. View

5.
Ahola T, Manninen T, Alkio N, Ylikomi T . G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology. 2002; 143(9):3376-84. DOI: 10.1210/en.2001-211445. View